TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.7835 +0.0047 (+0.60%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist

Price and Volume

Volume	360,270
Open	0.7800
Bid (Size)	0.7250 (1,300)
Ask (Size)	0.7940 (300)
Prev. Close	0.7788
Today's Range	0.7625 - 0.7950
52wk Range	0.7160 - 2.570
Shares Outstanding	23,976,942
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026

Actively enrolling patients across the US with anticipated topline data readout mid-2028

From TScan Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-23.2%	-23.2%
1 Month	-14.4%	-14.4%
3 Month	-21.7%	-21.7%
6 Month	-19.7%	-19.7%
1 Year	-56.2%	-56.2%

More News

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 03, 2026

From Cellares

Via Business Wire

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 06, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

April 27, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 04, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

February 26, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

December 03, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

November 05, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 04, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

November 03, 2025

Via Chartmill

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

November 03, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

Which stocks are moving on Wednesday? ↗

October 01, 2025

Via Chartmill

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

September 17, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

TScan Therapeutics to Participate in Upcoming Investor Conferences

September 03, 2025

From TScan Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is TScan Therapeutics, Inc. - Common Stock publicly traded?

Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does TScan Therapeutics, Inc. - Common Stock trade on?

TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?

The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market

What is the current price of TScan Therapeutics, Inc. - Common Stock?

The current price of TScan Therapeutics, Inc. - Common Stock is 0.7835

When was TScan Therapeutics, Inc. - Common Stock last traded?

The last trade of TScan Therapeutics, Inc. - Common Stock was at 08/17/26 04:00 PM ET

What is the market capitalization of TScan Therapeutics, Inc. - Common Stock?

The market capitalization of TScan Therapeutics, Inc. - Common Stock is 18.79M

How many shares of TScan Therapeutics, Inc. - Common Stock are outstanding?

TScan Therapeutics, Inc. - Common Stock has 19M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.